News Article

Dechra

23 February 2022

Cheshire-headquartered veterinary pharmaceuticals business Dechra has said future prospects "remain excellent" after posting a surge in revenues.

For the six months ended 31 December 2021, revenues at the Northwich-based company increased to £332.4m from £299.8m in the prior period.

Operating profits also rose from £80.8m to £93.9m. EBIDTA was at £101.3m compared to £88.2m in 2020.

In a trading update on the London Stock Exchange, the group said it outperformed a market that has seen strong growth as it continued to benefit in major international markets from increased spending on pets as a result of Covid-19 restrictions.

It said the growth had been achieved across all product categories and all major therapeutic areas. 

Strategic progress was also made through the acquisition of a number of complementary products and through progress in its product development pipeline. 

Read more at: Insider Media